Alzheimer blood test could be game-changer for early detection
Alzheimer blood test could be game-changer for early detection
Alzheimer's disease is the most common form of dementia
Doctors expressed optimism at the progress researchers have made with a new blood test aimed at detecting Alzheimer’s disease at an early stage.
They told FOX Business that they have waited years for a more accessible and affordable way to detect the disease, and now, it is one step closer to becoming a reality.
The latest development of the test, published in JAMA Neurology on Monday, revealed a protein called phosphorylated tau 217 assay could be used to detect the disease before the onset of symptoms.
Test researchers discovered that p-tau217 assay has greater than 90% accuracy for diagnosing Alzheimer’s disease, Dr. Sharon Cohen, a behavioral neurologist, told FOX Business.
ALZHEIMER’S DRUG LEQEMBI: WHAT TO KNOW
The data underscored how the blood test can track disease progression without forcing patients to go through the expensive positron emission tomography (PET) scans and invasive procedures such as spinal fluid assessments, according to Cohen and New York City-based emergency room physician Dr. Robert Glatter.
It has been a long time coming.
"We have wanted a blood test for Alzheimer's for years, and initially that just seemed impossible," Cohen said. However, given that "the need is so great to have an accessible, affordable way of diagnosing Alzheimer's disease early in the disease when treatments might be helpful, scientists around the world have continued to work on this."
A test like this can make an early and accurate diagnosis more readily available.
Cohen and Glatter believe it can be a game-changer for Alzheimer's disease, which is the most common type of dementia, because it can lead to improved patient care and treatment options.
FDA TO DECIDE ON FULL APPROVAL OF ALZHEIMER'S TREATMENT LEQEMBI IN EARLY JULY
According to latest estimates from the Centers for Disease Control and Prevention, about 6.7 million Americans who are at least 65 years old are living with Alzheimer's in 2023. However, that figure is expected to nearly triple to 14 million people by 2060.
"Having such a blood test with high accuracy will be a game change in the management of patients at higher risk for Alzheimer’s Disease, especially those who have a strong family history," Glatter said.
Comments